Natural Coptidis Rhizoma Nanoparticles Improved the Oral Delivery of Docetaxel
Dan Ye,Ding Ding,Ling-Yun Pan,Qing Zhao,Long Chen,Min Zheng,Tong Zhang,Bing-Liang Ma
DOI: https://doi.org/10.2147/ijn.s470853
IF: 7.033
2024-08-18
International Journal of Nanomedicine
Abstract:Dan Ye, 1 Ding Ding, 1 Ling-Yun Pan, 2 Qing Zhao, 3 Long Chen, 2 Min Zheng, 1 Tong Zhang, 1 Bing-Liang Ma 1 1 Department of Pharmacology, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China; 2 Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China; 3 Department of Pharmacy, Jing'an District Zhabei Central Hospital, Shanghai, 200070, People's Republic of China Correspondence: Bing-Liang Ma; Tong Zhang, Department of Pharmacology, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, No. 1200 Cai Lun Road, Pudong New District, Shanghai, 201203, People's Republic of China, Tel +86-021-5132 2199 ; +86-021-5132 2318, Fax +86-021-5132 2192, Email ; Purpose: Docetaxel (DTX) is a valuable anti-tumor chemotherapy drug with limited oral bioavailability. This study aims to develop an effective oral delivery system for DTX using natural nanoparticles (Nnps) derived from Coptidis Rhizoma extract. Methods: DTX-loaded self-assembled nanoparticles (Nnps-DTX) were created using an optimized heat-induction strategy. Nnps-DTX's shape, size, Zeta potential, and in vitro stability were all carefully examined. Additionally, the study investigated the encapsulation efficiency, loading capacity, crystal form, and intermolecular interactions of DTX in Nnps-DTX. Subsequently, the solubility, release, cellular uptake, metabolic stability, and preclinical pharmacokinetics of DTX in Nnps-DTX were systematically evaluated. Finally, the cytotoxicity of Nnps-DTX was assessed in three tumor cell lines. Results: Nnps-DTX was spherical in shape, 138.6 ± 8.2 nm in size, with a Zeta potential of − 20.8 ± 0.6 mV, a DTX encapsulation efficiency of 77.6 ± 8.5%, and a DTX loading capacity of 6.8 ± 1.9%. Hydrogen bonds, hydrophobic interactions, and electrostatic interactions were involved in the formation of Nnps-DTX. DTX within Nnps-DTX was in an amorphous form, resulting in enhanced solubility (23.3 times) and release compared to free DTX. Following oral treatment, the mice in the Nnps-DTX group had DTX peak concentrations 8.8, 23.4, 44.6, and 5.7 times higher in their portal vein, systemic circulation, liver, and lungs than the mice in the DTX group. Experiments performed in Caco-2 cells demonstrated a significant increase in DTX uptake by Nnps-DTX compared to free DTX, which was significantly inhibited by indomethacin, an inhibitor of caveolae-mediated endocytosis. Furthermore, compared to DTX, DTX in Nnps-DTX demonstrated better metabolic stability in liver microsomes. Notably, Nnps-DTX significantly reduced the viability of MCF-7, HCT116, and HepG2 cells. Conclusion: The novel self-assembled nanoparticles considerably enhanced the cellular absorption, solubility, release, metabolic stability, and pharmacokinetics of oral DTX and demonstrated strong cytotoxicity against tumor cell lines. Keywords: docetaxel, oral delivery, self-assembly, nanoparticles, pharmacokinetics, coptidis rhizoma Graphical Docetaxel (DTX), a semi-synthetic analog of paclitaxel, is one of the most valuable anti-tumor chemotherapy drugs. 1 DTX inhibits tumor cells by inducing tubulin polymerization into microtubules and inhibiting microtubule depolymerization. 1 Clinically, DTX is mainly used to treat locally advanced or metastatic breast cancer 2 and non-small-cell lung cancer. 3 Due to low water solubility, poor permeability, and extensive first-pass metabolism, the oral bioavailability of DTX is as low as 7.39%. 4 As a result, in clinical practice, DTX is administered via injection. 1 However, severe blood adverse events, primarily neutropenia, 5 are frequently brought on by injection-caused high blood concentrations. In addition, DTX injections cause allergic reactions. 5 Oral DTX preparation with high bioavailability is one of the hottest areas of research. 6 Oral DTX has the advantage of being more effective and having fewer side effects than the injection, as oral DTX can be maintained in appropriate concentrations in the body for an extended duration. 6 For example, an oral nanoemulsion increased the oral bioavailability of DTX by 2.49 times and had a stronger anti-breast cancer effect in experimental animals than conventional injections. 4 However, synthetic nanomaterials frequently include organic reagents, raising safety apprehensions. 4,5 Drug carriers have the ability to attach drugs through both chemical bonding and physical adsorption, thereby regulating -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology